FS Development Corp. II FSII
Set alert
9.80 +9.80 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 252.44M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.21
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 11.72
- 200-d avg
- 10.42
- 1y target
- 6.20
Key statistics
- Market cap
- 252.44M
- Enterprise value
- 252.39M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 48.33K
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 20.73M
- Short % of float
- 0.24%
- 50-day average
- 11.72
- 200-day average
- 10.42
Analyst view
Consensus: underperform
Underperform
Price target (mean) 6.20
Next earnings
Consensus EPS estimate 0.00.
About FS Development Corp. II
As of December 23, 2021, FS Development Corp. II was acquired by FS Development Corp. II, in a reverse merger transaction. FS Development Corp. II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in San Francisco, California.
- Sector
- Financial Services
- Industry
- Shell Companies
- Country
- United States
News
- Pardes Biosciences and FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Advancing Oral Antiviral Drugs to Treat and Prevent SARS-CoV-2 Infections
- 2 New Healthcare SPACs Worth Adding to Your Watch List
- U.S. IPO Weekly Recap: The IPO Market Takes Its Annual February Break In A 1 IPO Week
- FS Development Corp. II, Sponsored by Foresite Capital, Announces Pricing of Upsized $175 Million Initial Public Offering
- Benzinga'a M&A Chatter for Monday August 13, 2012
Your note
Sign in to keep a note on FSII — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FS DEVELOPMENT HOLDINGS II, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 18, 2021 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Arena Capital Advisors, LLC- CA | 9.87% | 2,045,598 | 20.35M | Sep 29, 2021 |
| Price (T.Rowe) Associates Inc | 8.04% | 1,666,691 | 16.58M | Sep 29, 2021 |
| PFM Health Sciences, LP | 4.82% | 1,000,000 | 9.95M | Sep 29, 2021 |
| Adage Capital Partners GP L.L.C. | 4.82% | 1,000,000 | 9.95M | Sep 29, 2021 |
| RA Capital Management, L.P. | 4.82% | 1,000,000 | 9.95M | Sep 29, 2021 |
| JS Capital Management LLC | 4.82% | 1,000,000 | 9.95M | Sep 29, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) New Horizons Fund | 3.97% | 823,052 | 8.19M | Sep 29, 2021 |
| Blackstone Alternative Multi-Strategy Fund | 1.83% | 379,005 | 3.77M | Sep 29, 2021 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 0.79% | 164,600 | 1.67M | Oct 30, 2021 |
| Price (T.Rowe) New Horizons Trust | 0.50% | 102,731 | 1.02M | Sep 29, 2021 |
| John Hancock Fds II-Health Sciences Fund | 0.11% | 22,037 | 217.94K | Aug 30, 2021 |
| Special Opportunities Fd | 0.10% | 20,000 | 199.00K | Sep 29, 2021 |